U.S. intelligence officials in late February informed senators that Chinese pharmaceutical firm WuXi AppTec had transferred U.S. intellectual property to Beijing without consent, leading to an intraday gain narrowing to 1%. This incident has heightened concerns among the biotech community, with professionals being advised to assume their intellectual property is compromised if they have engaged WuXi AppTec for CRO or CDMO services. The revelation has sparked discussions around potential criminal charges against WuXi AppTec and speculation on which CDMOs might benefit. The BIOSECURE Act, being worked on by senators, is seen as almost a certainty in light of these developments.